CDH2 and prostate carcinoma: Among them, development of antibodies against the surface biomarkers including those EMT markers such as N-cadherin, CSC markers such as CD133, and specific signaling molecule such as HSP27 is the easier approach than targeting the transcription factors or cytoplasmic molecules and might hold promise for a novel therapeutic approach for the treatment of prostate cancer.